Genmab Announces Financial Results for the First Quarter of 2015
May 12, 2015 11:02 ET
|
Genmab A/S
May 12, 2015; Copenhagen, Denmark;
Interim Report First Quarter 2015
Positive preliminary results from the Phase II study of daratumumab in double refractory multiple myeloma
Positive...
First Quarter 2015 Net Sales Figures for Arzerra® (Ofatumumab)
May 06, 2015 07:02 ET
|
Genmab A/S
Company Announcement
Worldwide net sales of Arzerra® in Q1 2015 totaled GBP 11.1 million
Genmab expects royalty payment of approximately DKK 22 million
Copenhagen, Denmark; May 6, 2015 –...
Nettoomsætning for Arzerra® (ofatumumab) i første kvartal 2015
May 06, 2015 07:02 ET
|
Genmab A/S
Selskabsmeddelelse
Den globale nettoomsætning for Arzerra® i første kvartal 2015 udgjorde GBP 11,1 mio.
Genmab forventer royaltybetaling på ca. DKK 22 mio.
København, Danmark, 6. maj...
Genmab Announces Phase III Study of Arzerra® Met Primary Endpoint of Improved Progression-Free Survival in Patients with Relapsed CLL
April 27, 2015 10:17 ET
|
Genmab A/S
Company Announcement
Positive top-line results seen with Arzerra plus fludarabine and cyclophosphamide in chronic lymphocytic leukemia (CLL) patients when prior treatment stopped...
Genmab meddeler, at fase III studie med Arzerra® har nået det primære endpoint om forbedret progressionsfri overlevelse hos patienter med recidiverende CLL
April 27, 2015 10:17 ET
|
Genmab A/S
Selskabsmeddelelse
Positive top-line resultater opnået med Arzerra plus fludarabin og cyclofosfamid til behandling af patienter med kronisk lymfatisk leukæmi (CLL), efter at tidligere...
Genmab Achieves USD 10 Million Milestone in Daratumumab Collaboration with Janssen
April 16, 2015 09:36 ET
|
Genmab A/S
Company Announcement
Genmab to receive USD 10 million milestone payment from Janssen
Milestone triggered by progress in the Phase III study in patients with multiple myeloma of daratumumab...
Genmab opnår milestonebetaling på USD 10 mio. i daratumumab-samarbejdet med Janssen
April 16, 2015 09:36 ET
|
Genmab A/S
Selskabsmeddelelse
Genmab vil modtage milestonebetaling fra Janssen på USD 10 mio.
Milestonebetalingen er udløst af fremskridt i fase III studiet med daratumumab i kombination med...
Selskabsvedtægter for Genmab A/S
April 01, 2015 11:19 ET
|
Genmab A/S
Selskabsvedtægter for Genmab A/S dateret den 26. marts 2015 er blevet offentliggjort. Selskabsvedtægterne er tilgængelige på Genmabs hjemmeside:...
Articles of Association for Genmab A/S
April 01, 2015 11:19 ET
|
Genmab A/S
Genmab A/S has published its Articles of Association dated March 26, 2015. The Articles of Association can be found on Genmab’s website: http://ir.genmab.com/releases.cfm
Contact:
Rachel Curtis...
Genmab’s Total Number of Voting Rights and Total Share Capital
March 31, 2015 11:28 ET
|
Genmab A/S
Company Announcement
Publication of voting rights and share capital
Copenhagen, Denmark; March 31, 2015 – Genmab A/S (OMX: GEN) announces that pursuant to section 6 of Executive Order no....